Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Key Takeaway: Insmed Incorporated announced the granting of inducement awards to 17 new employees in accordance with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase an aggregate of 136,800 shares of the company's common stock at a price corresponding to the market close on the grant date. The options include a 10-year term and a structured four-year vesting schedule. This initiative underscores Insmed's focus on expanding its workforce to enhance its operations in the biopharmaceutical sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed awarded inducement grants to 17 new employees, enhancing its workforce.
  • The stock options have a long tenure and structured vesting, encouraging employee retention.
  • This move aligns with Insmed's commitment to attract top talent in biopharmaceuticals.

Full Press Release Details

BRIDGEWATER, N.J. , March 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 17 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on March 1, 2023 to purchase an aggregate 136,800 shares of Insmed common stock at an exercise price of $20.24 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

What inducement awards did Insmed grant to new employees?

Insmed awarded inducement options to 17 new employees as a hiring incentive.

How many shares were granted as options to Insmed employees?

The employees were granted options to purchase a total of 136,800 shares.

What is the exercise price for the granted options?

The exercise price for the options is set at $20.24 per share.

What is the vesting schedule for the options at Insmed?

The options vest over four years, with 25% on the first anniversary and 12.5% semi-annually thereafter.

What is Insmed's primary mission?

Insmed aims to transform the lives of patients with serious and rare diseases.

Last updated: Mar 3, 2023